e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Citic Ltd Ord
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Summit Therapeutics Inc. - Common Stock
(NQ:
SMMT
)
10.50
-0.17 (-1.59%)
Delayed Quote
Updated: 4:00 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Summit Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer
November 18, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
November 15, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
November 04, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
October 25, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
October 23, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
October 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
October 21, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
October 19, 2026
From
Summit Therapeutics
Via
Business Wire
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
October 05, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 02, 2026
From
Summit Therapeutics
Via
Business Wire
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
September 28, 2026
From
Summit Therapeutics
Via
Business Wire
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
September 22, 2026
From
Summit Therapeutics
Via
Business Wire
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
September 13, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
September 02, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
August 25, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
August 25, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
August 12, 2026
From
Summit Therapeutics
Via
Business Wire
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
August 06, 2026
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
August 05, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From
Summit Therapeutics
Via
Business Wire
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 04, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
May 31, 2026
From
Summit Therapeutics
Via
Business Wire
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
May 30, 2026
From
Summit Therapeutics
Via
Business Wire
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026
From
USA News Group
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.